SCHEMBL20234548

SCHEMBL20234548

CNC(=O)CCCCOCCCOCCNC(=O)CCCOCCCCOC

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.56
▸ HPGD P15428 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ CNR1 P21554 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ RECQL P46063 1/20 0.39
▸ ENPP2 Q13822 1/20 0.37
▸ LPAR1 Q92633 1/20 0.37
▸ LPAR2 Q9HBW0 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20325455 0.95 TSHR (0.54) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20330043 0.95 TSHR (0.54) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20463183 0.95 TSHR (0.50) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20322418 0.95 TSHR (0.50) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20322419 0.95 TSHR (0.57) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL16216957 0.94 TSHR (0.64) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20372893 0.93 TSHR (0.54) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20330001 0.91 TSHR (0.59) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20230958 0.89 TSHR (0.48) TSHRHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL21649546 0.88 TSHR (0.49) TSHRHPGDMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2021-07-20 — — US disclosed
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 — — US disclosed
US-20200121684-A1 MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE UNIV YALE (US) 2020-04-23 — — US disclosed
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2019-10-03 — — US disclosed
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES ARVINAS OPERATIONS, INC. 2019-05-23 — — US disclosed
US-20180179183-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES ARVINAS OPERATIONS, INC. 2018-06-28 — — US disclosed
US-20180155322-A1 TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS OPERATIONS, INC. 2018-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179183-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL TSHR 2304/4885HPGD 4053/4885MEN1 2317/4885
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES IRAK1, IRAK4, IRAK2 TSHR 3443/4885HPGD 2784/4885MEN1 2454/4885
US-20200121684-A1 MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE BTK, CBL, CRBN TSHR 4036/4885HPGD 4471/4885MEN1 2657/4885
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 TSHR 3443/4885HPGD 2784/4885MEN1 2454/4885
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL TSHR 3232/4885HPGD 4163/4885MEN1 2768/4885
US-20180155322-A1 TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS MDM2, CRBN, VHL TSHR 2675/4885HPGD 1369/4885MEN1 2168/4885
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL TSHR 2304/4885HPGD 4053/4885MEN1 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback